Vaccines Market

研究執行與發布：MarketsandMarkets　·　發布日期 2026-08-10　·　440 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

完整報告名稱與涵蓋範圍

Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, mRNA), Type (Multivalent, Monovalent), Disease (Pneumococcal, Flu, Hepatitis, MMR, Rotavirus, RSV, HPV, Polio), ROA (IM, SC, Oral), Competition - Global Forecast to 2031

報告摘要

The vaccines market (excluding COVID-19) is expected to reach USD 71.14 billion in 2031, up from USD 55.68 billion in 2026, growing at a CAGR of 5.0% during the forecast period. Factors such as the high incidence of contagious diseases, innovation in vaccine technology, government support and substantial funding for vaccine development, increasing vaccination initiatives, and a strong focus on investing in and launching innovative products are driving this growth in vaccines. By disease indication, the pneumococcal segment accounted for the largest share of the vaccines market in 2025. Based on disease indication, the vaccines market is segmented into combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, COVID-19, and other disease indications. In 2025, the pneumococcal segment held the largest share of the vaccines market. This is due to several key factors: a rising incidence of pneumococcal infections worldwide; increased government funding for vaccination programs; and heightened public awareness of the serious health risks associated with pneumococcal-related complications such as pneumonia, meningitis, and bloodstream infections. Additionally, ongoing innovation and the development of next-generation pneumococcal vaccines, such as the recently approved 20-valent and 21-valent conjugate vaccines, are expanding immunization options, further boosting market growth and public health benefits. By type, the multivalent vaccines segment accounted for the largest share of the vaccines market in 2025. The vaccines market is divided into monovalent vaccines and multivalent vaccines, based on type. In 2025, the multivalent vaccines segment held the largest portion of the Vaccines market. This dominance stems from multivalent vaccines' ability to protect against multiple diseases with a single dose—simplifying immunization by reducing the number of injections needed, which increases patient compliance and decreases logistical challenges. Additionally, the growing prevalence of diseases that require broad-spectrum immunity, such as respiratory infections and certain cancers, has increased demand for these vaccines. Further supporting this trend are technological advances and increased investment in efficient manufacturing of multivalent vaccines, enabling larger and faster production. Governments and healthcare providers in regions with limited healthcare access particularly favor them because simplified vaccination schedules improve coverage and boost public health outcomes. The Asia Pacific region is expected to grow at the highest CAGR in the vaccines market from 2026 to 2031. The vaccines market region is divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to grow at a significant CAGR during the forecast period. This increase is driven by greater public health awareness, expanding national immunization programs, and increased government investment in healthcare infrastructure. Supporting these efforts are public–private partnerships, international collaborations aimed at improving vaccine equity, and technological advancements that enable advanced vaccine development and more affordable production. Additionally, the region’s large and growing populations, especially in countries such as China and India, present a substantial target market for both established and new vaccines. These factors highlight the Asia Pacific’s leadership in the vaccine industry market. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side (80%) and Demand Side (20%) • By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%) • By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%) Pfizer, Inc. (US), GSK Plc (UK), Merck & Co., Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd. (India) are some of the key companies offering vaccines. Research Coverage This research report categorizes the vaccines market by technology (conjugate vaccines, recombinant vaccines, inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, and other vaccines), type (monovalent vaccines and multivalent vaccines), indication (pneumococcal disease, influenza, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, varicella, hepatitis, DTP, polio, RSV, COVID-19, and other disease indications), route of administration (intramuscular & subcutaneous administration, oral administration, and other routes of administration), end user (pediatric vaccines and adult vaccines), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report provides detailed information on major factors such as drivers, challenges, opportunities, and restraints that influence the growth of the vaccines market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, product portfolios, and key strategies, including collaborations, partnerships, expansions, agreements, acquisitions, and recent developments related to the vaccines market. This report includes a competitive analysis of top players and upcoming startups within the vaccines market ecosystem. The report also details primary factors like drivers, restraints, challenges, and opportunities shaping the market growth, along with an in-depth review of key industry players’ solutions, products, recent product launches, mergers, acquisitions, and emerging market trends ecosystem. Key Benefits of Buying the Report This report offers a comprehensive overview of the vaccines market. It aims to assess the size and future growth opportunities of the market across various segments, such as technology, type, indication, route of administration, end user, and region. The report also features an in-depth competitive analysis of the major market players, including their company profiles, recent developments, and key market strategies. The report provides insights into the following pointers: Analysis of key drivers (focus on vaccine development and launches, rising prevalence of infectious diseases, increasing immunization programs, advancements in vaccine technology, and government support & funding for vaccine development), restraints (high cost of vaccine development), opportunities (rising focus on therapeutic vaccines, extensive R&D for vaccines, and increased investments in clinical trials), and challenges (stringent regulatory processes and product recalls) • Product Development/Innovation: Detailed insights on newly launched products and technological assessment of the vaccines market. • Market Development: Comprehensive information about lucrative markets; the report analyzes the vaccines market across varied regions. • Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the vaccines market Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as GSK plc (UK), Merck & Co., Inc. (US), Pfizer, Inc. (US), Sanofi (France), CSL (Australia), Emergent (US), Johnson & Johnson Services Inc. (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo Company, Limited (Japan), Panacea Biotec (India), Biological E. Limited (India), Bharat Biotech (India), Novavax (US), Inovio Pharmaceuticals (US), Sinovac (China), Incepta Pharmaceuticals (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), Bio Farma (Indonesia), FSUE NPO Microgen (Russia), Zhi Fei Biological (China), and Indian Immunologicals Ltd (India), among others, in the vaccines market. The report also helps stakeholders understand the trends of the vaccines market and provides information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of key industry players has been conducted to offer insights into their key strategies, product launches and approvals, pipeline developments, acquisitions, partnerships, collaborations, recent activities, investments and funding, brand and product comparisons, vendor evaluations, and financial metrics of the vaccines market.

授權報價

Single User Licence	$4,950 USD
Multi User Licence	$6,650 USD
Corporate User Licence	$8,150 USD
Global User Licence	$10,000 USD

目錄 Table of Contents

1 INTRODUCTION 39 1.1 STUDY OBJECTIVES 39 1.2 MARKET DEFINITION 39 1.3 STUDY SCOPE 40 1.3.1 MARKET SEGMENTATION & REGIONS COVERED 40 1.3.2 INCLUSIONS & EXCLUSIONS 41 1.3.3 YEARS CONSIDERED 41 1.3.4 CURRENCY CONSIDERED 42 1.4 STAKEHOLDERS 42 1.5 SUMMARY OF CHANGES 42 2 EXECUTIVE SUMMARY 44 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 44 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS IN VACCINES MARKET 47 2.4 HIGH-GROWTH SEGMENTS 48 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 51 3.1 VACCINES MARKET OVERVIEW 51 3.2 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE AND COUNTRY, 2025 52 3.3 VACCINES MARKET (EXCLUDING COVID-19 VACCINES): GEOGRAPHIC GROWTH OPPORTUNITIES 53 3.4 VACCINES MARKET (EXCLUDING COVID-19 VACCINES) SHARE, BY ROUTE OF ADMINISTRATION, 2026 VS 2031 (%) 54 4 MARKET OVERVIEW 55 4.1 INTRODUCTION 55 4.2 MARKET DYNAMICS 55 4.2.1 DRIVERS 56 4.2.1.1 Focus on vaccine development and launches 56 4.2.1.2 Rising prevalence of infectious diseases 58 4.2.1.3 Increasing immunization programs 59 4.2.1.4 Advancements in vaccine technology 60 4.2.1.5 Government support and funding for vaccine development 61 4.2.2 RESTRAINTS 62 4.2.2.1 High cost of vaccine development 62 4.2.3 OPPORTUNITIES 64 4.2.3.1 Rising focus on therapeutic vaccines 64 4.2.3.2 Extensive R&D for vaccines and increased investments in clinical trials 67 4.2.4 CHALLENGES 67 4.2.4.1 Stringent regulatory processes 67 4.2.4.2 Product recalls 68 4.3 UNMET NEEDS & WHITE SPACES 69 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 70 5 INDUSTRY TRENDS 72 5.1 PORTER’S FIVE FORCES ANALYSIS 72 5.1.1 BARGAINING POWER OF SUPPLIERS 73 5.1.2 BARGAINING POWER OF BUYERS 73 5.1.3 THREAT OF NEW ENTRANTS 73 5.1.4 THREAT OF SUBSTITUTES 73 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74 5.2 MACROECONOMIC OUTLOOK 74 5.2.1 INTRODUCTION 74 5.2.2 GDP TRENDS & FORECAST 74 5.2.3 TRENDS IN GLOBAL VACCINES INDUSTRY 75 5.3 VALUE CHAIN ANALYSIS 76 5.4 PIPELINE ANALYSIS 77 5.4.1 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 77 5.4.2 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 77 5.4.3 VACCINES MARKET: PHASE 2/3 CLINICAL TRIALS, BY COMPANY 81 5.5 ECOSYSTEM ANALYSIS 83 5.6 PRICING ANALYSIS 85 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 86 5.6.2 AVERAGE SELLING PRICE TREND, BY DISEASE INDICATION, 2024–2026 88 5.6.3 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024 89 5.7 TRADE ANALYSIS 91 5.7.1 IMPORT SCENARIO (HS CODE 300220) 91 5.7.2 EXPORT SCENARIO (HS CODE 300220) 93 5.8 KEY CONFERENCES AND EVENTS, 2026–2027 94 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 95 5.10 INVESTMENT AND FUNDING SCENARIO 96 5.10.1 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 97 5.11 IMPACT OF 2025 US TARIFFS—VACCINES MARKET 98 5.11.1 INTRODUCTION 98 5.11.2 KEY TARIFF RATES 98 5.11.3 PRICE IMPACT ANALYSIS 99 5.11.4 IMPACT ON COUNTRIES/REGIONS 99 5.11.4.1 US 99 5.11.4.2 Europe 100 5.11.4.3 Asia Pacific 100 5.11.5 IMPACT ON END-USE INDUSTRIES 100 5.11.5.1 Public health & government bodies 100 5.11.5.2 Healthcare providers & institutions 101 5.12 VACCINE PROCUREMENT DATA 101 5.12.1 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026 101 5.12.2 WHO: VACCINE PURCHASE DATABASE, 2022–2024 102 5.13 VACCINE MANUFACTURING PROCESS 104 5.13.1 OVERVIEW 104 5.13.1.1 R&D and process development 104 5.13.1.2 Upstream production (antigen generation) 105 5.13.1.3 Downstream processing 105 5.13.1.4 Formulation & fill-finish 105 5.13.1.5 Quality control & regulatory release 105 5.13.1.6 Packaging, cold chain, and distribution 105 5.13.2 MANUFACTURING MODELS & CAPACITY DYNAMICS 105 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, AND INNOVATIONS 108 6.1 TECHNOLOGY ANALYSIS 108 6.1.1 KEY EMERGING TECHNOLOGIES 108 6.1.1.1 Recombinant technology 108 6.1.1.2 Conjugation technology 108 6.1.1.3 Viral vector technology 109 6.1.2 COMPLEMENTARY TECHNOLOGIES 109 6.1.2.1 Encapsulation & delivery technology 109 6.1.2.2 Automation & control 109 6.1.2.3 AI & machine learning for vaccine design 110 6.1.3 ADJACENT TECHNOLOGIES 110 6.1.3.1 Single-use technology 110 6.1.3.2 Cell line development 110 6.2 TECHNOLOGY/PRODUCT ROADMAP 111 6.3 PATENT ANALYSIS 111 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS 112 6.4 FUTURE APPLICATIONS 114 6.5 IMPACT OF AI/GEN AI—VACCINES MARKET 115 6.5.1 BEST PRACTICES IN VACCINES WORKFLOW 116 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET 117 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 117 6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VACCINES MARKET 118 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 119 7.1 REGIONAL REGULATIONS AND COMPLIANCE 119 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119 7.1.2 REGULATORY FRAMEWORK 122 7.1.2.1 North America 122 7.1.2.2 Europe 122 7.1.2.3 Asia Pacific 123 7.1.2.4 Latin America 123 7.1.2.5 Middle East & Africa 123 7.1.3 REGULATORY CHALLENGES IN VACCINES MARKET 124 7.1.4 INDUSTRY STANDARDS 124 7.2 SUSTAINABILITY INITIATIVES 125 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY 125 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 126 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 127 8.1 DECISION-MAKING PROCESS 127 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 127 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 127 8.2.2 KEY BUYING CRITERIA, BY END USER 129 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 130 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 131 8.5 MARKET PROFITABILITY 131 9 VACCINES MARKET, BY DISEASE INDICATION 132 9.1 INTRODUCTION 133 9.2 PNEUMOCOCCAL DISEASE 134 9.2.1 EXPANDING ADULT IMMUNIZATION PROGRAMS AND HIGHER-VALENCY VACCINES TO DRIVE MARKET 134 9.3 INFLUENZA 138 9.3.1 SEASONAL IMMUNIZATION PROGRAMS AND EXPANDING ADULT VACCINATION TO DRIVE MARKET 138 9.4 HPV 142 9.4.1 EXPANDING NATIONAL HPV IMMUNIZATION PROGRAMS AND RISING ADOPTION OF GENDER-NEUTRAL VACCINATION TO DRIVE THE FASTEST-GROWING SEGMENT 142 9.5 HERPES ZOSTER 146 9.5.1 RISING AGING POPULATION TO DRIVE DEMAND FOR HERPES ZOSTER VACCINES 146 9.6 COMBINATION VACCINES 150 9.6.1 EXPANDING NATIONAL IMMUNIZATION PROGRAMS AND GROWING PREFERENCE FOR MULTI-ANTIGEN VACCINES TO DRIVE MARKET 150 9.7 MENINGOCOCCAL DISEASE 154 9.7.1 EXPANDING IMMUNIZATION RECOMMENDATIONS AND BROADER SEROGROUP COVERAGE TO SUPPORT MARKET GROWTH 154 9.8 ROTAVIRUS 158 9.8.1 RISING INFANT IMMUNIZATION PROGRAMS TO DRIVE ROTAVIRUS MARKET GROWTH 158 9.9 RSV 161 9.9.1 INITIAL VACCINE UPTAKE AND EXPANDING IMMUNIZATION RECOMMENDATIONS SUPPORT MARKET PENETRATION 161 9.10 DTP 165 9.10.1 CONTINUED ROUTINE CHILDHOOD IMMUNIZATION AND BOOSTER VACCINATION PROGRAMS TO SUPPORT MARKET 165 9.11 HEPATITIS 168 9.11.1 EXPANDING HEPATITIS B IMMUNIZATION AND GLOBAL ELIMINATION INITIATIVES TO SUPPORT MARKET GROWTH 168 9.12 VARICELLA 172 9.12.1 EXPANDING CHILDHOOD IMMUNIZATION PROGRAMS AND INCREASING ADOPTION OF VARICELLA VACCINES TO SUPPORT MARKET GROWTH 172 9.13 MMR 175 9.13.1 RISING MEASLES OUTBREAKS AND IMMUNIZATION RECOVERY EFFORTS TO SUPPORT MARKET GROWTH 175 9.14 POLIO 178 9.14.1 GLOBAL POLIO ERADICATION INITIATIVES AND CONTINUED VACCINATION CAMPAIGNS TO SUSTAIN MARKET DEMAND 178 9.15 COVID-19 181 9.15.1 SHIFT FROM PANDEMIC-DRIVEN DEMAND TO ENDURING HIGH-RISK POPULATION VACCINATION, RESULTING IN MARKET NORMALIZATION 181 9.16 OTHER DISEASE INDICATIONS 184 10 VACCINES MARKET, BY TECHNOLOGY 188 10.1 INTRODUCTION 189 10.2 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY 189 10.2.1 RECOMBINANT VACCINES 190 10.2.1.1 Broader adult immunization and continued recombinant vaccine launches to drive market 190 10.2.2 CONJUGATE VACCINES 193 10.2.2.1 Higher-valency pneumococcal vaccines and large public immunization programs to drive market 193 10.2.3 INACTIVATED & SUBUNIT VACCINES 196 10.2.3.1 Recurring influenza demand and wider access to established non-live vaccines to support market 196 10.2.4 LIVE ATTENUATED VACCINES 200 10.2.4.1 Durable immune protection and convenient oral or nasal administration to support market 200 10.2.5 TOXOID VACCINES 203 10.2.5.1 Routine pediatric boosters and maternal immunization programs to sustain market 203 10.2.6 OTHER VACCINES 206 10.3 COVID-19 VACCINES MARKET, BY TECHNOLOGY 210 10.3.1 MRNA VACCINES 210 10.3.1.1 Rapid variant adaptation and continued vaccination of high-risk populations to drive market 210 10.3.2 VIRAL VECTOR VACCINES 213 10.3.2.1 Withdrawal of first-generation products and shift toward updated vaccine platforms to accelerate market decline 213 10.3.3 OTHER COVID-19 VACCINES 216 11 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE 219 11.1 INTRODUCTION 220 11.2 MULTIVALENT VACCINES 220 11.2.1 BROADER SEROTYPE COVERAGE AND INCREASING ADOPTION OF COMBINATION IMMUNIZATION SCHEDULES TO DRIVE MARKET 220 11.3 MONOVALENT VACCINES 224 11.3.1 ESTABLISHED SINGLE-DISEASE PROGRAMS AND EXPANDING ADULT IMMUNIZATION INDICATIONS TO SUPPORT MARKET 224 12 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION 229 12.1 INTRODUCTION 230 12.2 INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 230 12.2.1 EASE OF ABSORPTION AND BETTER IMMUNE RESPONSE TO DRIVE ADOPTION 230 12.3 ORAL ADMINISTRATION 234 12.3.1 NEEDLE-FREE DELIVERY AND HIGH-VOLUME DISEASE-CONTROL CAMPAIGNS TO SUPPORT MARKET 234 12.4 OTHER ROUTES OF ADMINISTRATION 237 13 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER 241 13.1 INTRODUCTION 242 13.2 ADULT VACCINES 242 13.2.1 AGING POPULATIONS, BROADER ADULT INDICATIONS, AND GROWING LIFE-COURSE IMMUNIZATION TO DRIVE MARKET 242 13.3 PEDIATRIC VACCINES 245 13.3.1 EXPANDING CHILDHOOD IMMUNIZATION SCHEDULES AND NEW VACCINE INTRODUCTIONS TO DRIVE MARKET GROWTH 245 14 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION 249 14.1 INTRODUCTION 250 14.2 NORTH AMERICA 250 14.2.1 US 254 14.2.1.1 US to dominate North American market during forecast period 254 14.2.2 CANADA 257 14.2.2.1 Expansion of life-course immunization to support market growth 257 14.3 EUROPE 260 14.3.1 GERMANY 263 14.3.1.1 Adult immunization and updated national recommendations to drive market growth 263 14.3.2 UK 266 14.3.2.1 Expansion of adult and maternal immunization programs to support market growth 266 14.3.3 FRANCE 269 14.3.3.1 Favorable government initiatives for mass immunization to drive market 269 14.3.4 ITALY 272 14.3.4.1 Higher investments by companies for increased production capacities to drive market 272 14.3.5 SPAIN 275 14.3.5.1 Rising investments in vaccine development by private organizations to drive market 275 14.3.6 REST OF EUROPE 277 14.4 ASIA PACIFIC 280 14.4.1 CHINA 284 14.4.1.1 China to hold largest share of APAC vaccines market 284 14.4.2 JAPAN 287 14.4.2.1 Aging population and gradual expansion of routine vaccination to drive demand 287 14.4.3 INDIA 290 14.4.3.1 Large immunization requirements and manufacturing leadership to support strong growth 290 14.4.4 SOUTH KOREA 293 14.4.4.1 Strong government strategies for improved vaccine hubs to drive market 293 14.4.5 REST OF ASIA PACIFIC 296 14.5 LATIN AMERICA 299 14.5.1 BRAZIL 302 14.5.1.1 Strong public procurement and domestic manufacturing to drive market 302 14.5.2 MEXICO 305 14.5.2.1 Trained workforce and ethnically varied population base for clinical trials to propel market growth 305 14.5.3 REST OF LATIN AMERICA 308 14.6 MIDDLE EAST 310 14.6.1 GOVERNMENT-LED LOCALIZATION AND EXPANDING ADULT AND TRAVEL IMMUNIZATION TO SUPPORT MARKET GROWTH 310 14.7 AFRICA 313 14.7.1 HIGH UNMET IMMUNIZATION NEEDS AND LOCAL MANUFACTURING INITIATIVES TO DRIVE MARKET EXPANSION 313 15 COMPETITIVE LANDSCAPE 317 15.1 OVERVIEW 317 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 317 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN VACCINES MARKET 317 15.3 REVENUE ANALYSIS, 2021–2025 319 15.4 MARKET SHARE ANALYSIS, 2025 320 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 322 15.5.1 STARS 323 15.5.2 EMERGING LEADERS 323 15.5.3 PERVASIVE PLAYERS 323 15.5.4 PARTICIPANTS 323 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 325 15.5.5.1 Company footprint 325 15.5.5.2 Region footprint 325 15.5.5.3 Technology footprint 326 15.5.5.4 Type footprint 327 15.5.5.5 Route of administration footprint 328 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 328 15.6.1 PROGRESSIVE COMPANIES 328 15.6.2 RESPONSIVE COMPANIES 329 15.6.3 DYNAMIC COMPANIES 329 15.6.4 STARTING BLOCKS 329 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 330 15.6.5.1 Detailed list of key startups/SMEs 330 15.6.5.2 Competitive benchmarking of key startups/SMEs 331 15.7 COMPANY VALUATION & FINANCIAL METRICS 332 15.7.1 FINANCIAL METRICS 332 15.7.2 COMPANY VALUATION 332 15.8 PRODUCT COMPARISON 333 15.8.1 PRODUCT COMPARATIVE ANALYSIS 333 15.9 COMPETITIVE SCENARIO 334 15.9.1 PRODUCT LAUNCHES & APPROVALS 334 15.9.2 DEALS 335 15.9.3 EXPANSIONS 336 16 COMPANY PROFILES 337 16.1 KEY PLAYERS 337 16.1.1 PFIZER INC. 337 16.1.1.1 Business overview 337 16.1.1.2 Products offered 338 16.1.1.3 Recent developments 340 16.1.1.3.1 Product approvals 340 16.1.1.4 MnM view 341 16.1.1.4.1 Key strengths 341 16.1.1.4.2 Strategic choices 341 16.1.1.4.3 Weaknesses & competitive threats 341 16.1.2 GSK PLC 342 16.1.2.1 Business overview 342 16.1.2.2 Products offered 343 16.1.2.3 Recent developments 345 16.1.2.3.1 Product launches & approvals 345 16.1.2.3.2 Deals 347 16.1.2.3.3 Expansions 347 16.1.2.4 MnM view 348 16.1.2.4.1 Key strengths 348 16.1.2.4.2 Strategic choices 348 16.1.2.4.3 Weaknesses & competitive threats 348 16.1.3 MERCK & CO., INC. 349 16.1.3.1 Business overview 349 16.1.3.2 Products offered 350 16.1.3.3 Recent developments 352 16.1.3.3.1 Product approvals 352 16.1.3.3.2 Expansions 353 16.1.3.4 MnM view 353 16.1.3.4.1 Key strengths 353 16.1.3.4.2 Strategic choices 353 16.1.3.4.3 Weaknesses & competitive threats 353 16.1.4 SANOFI 354 16.1.4.1 Business overview 354 16.1.4.2 Products offered 355 16.1.4.3 Recent developments 357 16.1.4.3.1 Product approvals 357 16.1.4.3.2 Deals 357 16.1.4.3.3 Expansions 358 16.1.4.3.4 Other developments 359 16.1.4.4 MnM view 359 16.1.4.4.1 Key strengths 359 16.1.4.4.2 Strategic choices 359 16.1.4.4.3 Weaknesses & competitive threats 359 16.1.5 CSL 360 16.1.5.1 Business overview 360 16.1.5.2 Products offered 361 16.1.5.3 Recent developments 362 16.1.5.3.1 Product approvals 362 16.1.5.3.2 Deals 362 16.1.5.3.3 Expansions 363 16.1.6 EMERGENT 364 16.1.6.1 Business overview 364 16.1.6.2 Products offered 365 16.1.6.3 Recent developments 366 16.1.6.3.1 Product approvals 366 16.1.6.3.2 Deals 367 16.1.6.3.3 Other developments 367 16.1.7 JOHNSON & JOHNSON SERVICES, INC. 368 16.1.7.1 Business overview 368 16.1.7.2 Products offered 369 16.1.7.3 Recent developments 370 16.1.7.3.1 Deals 370 16.1.8 ASTRAZENECA 371 16.1.8.1 Business overview 371 16.1.8.2 Products offered 372 16.1.8.3 Recent developments 373 16.1.8.3.1 Deals 373 16.1.8.3.2 Expansions 373 16.1.9 SERUM INSTITUTE OF INDIA PVT. LTD. 374 16.1.9.1 Business overview 374 16.1.9.2 Products offered 374 16.1.9.3 Recent developments 377 16.1.9.3.1 Product launches & approvals 377 16.1.9.3.2 Deals 378 16.1.9.3.3 Expansions 380 16.1.10 BAVARIAN NORDIC 381 16.1.10.1 Business overview 381 16.1.10.2 Products offered 382 16.1.10.3 Recent developments 383 16.1.10.3.1 Product approvals 383 16.1.10.3.2 Deals 384 16.1.10.3.3 Other developments 385 16.1.11 TANABE PHARMA CORPORATION 386 16.1.11.1 Business overview 386 16.1.11.2 Products offered 386 16.1.11.3 Recent developments 387 16.1.11.3.1 Product launches & approvals 387 16.1.11.3.2 Deals 387 16.1.12 DAIICHI SANKYO COMPANY, LIMITED 388 16.1.12.1 Business overview 388 16.1.12.2 Products offered 389 16.1.12.3 Recent developments 390 16.1.12.3.1 Deals 390 16.1.13 PANACEA BIOTEC 391 16.1.13.1 Business overview 391 16.1.13.2 Products offered 392 16.1.13.3 Recent developments 393 16.1.13.3.1 Other developments 393 16.1.14 BIOLOGICAL E. LIMITED 394 16.1.14.1 Business overview 394 16.1.14.2 Products offered 394 16.1.14.3 Recent developments 396 16.1.14.3.1 Product approvals 396 16.1.14.3.2 Deals 397 16.1.14.3.3 Other developments 397 16.1.15 BHARAT BIOTECH 398 16.1.15.1 Business overview 398 16.1.15.2 Products offered 398 16.1.15.3 Recent developments 399 16.1.15.3.1 Product launches & approvals 399 16.1.15.3.2 Deals 400 16.1.16 NOVAVAX 401 16.1.16.1 Business overview 401 16.1.16.2 Products offered 402 16.1.16.3 Recent developments 402 16.1.16.3.1 Product approvals 402 16.1.16.3.2 Deals 403 16.1.17 INOVIO PHARMACEUTICALS 404 16.1.17.1 Business overview 404 16.1.17.2 Products offered 405 16.1.17.3 Recent developments 405 16.1.17.3.1 Other developments 405 16.2 OTHER PLAYERS 406 16.2.1 SINOVAC 406 16.2.2 INCEPTA PHARMACEUTICALS LTD. 408 16.2.3 VALNEVA SE 410 16.2.4 EUBIOLOGICS CO., LTD. 411 16.2.5 BIO FARMA 412 16.2.6 MICROGEN 414 16.2.7 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. 415 16.2.8 INDIAN IMMUNOLOGICALS LIMITED 416 17 RESEARCH METHODOLOGY 417 17.1 RESEARCH DATA 417 17.1.1 SECONDARY DATA 418 17.1.1.1 Key secondary sources 418 17.1.1.2 Key data from secondary research 418 17.1.2 PRIMARY DATA 419 17.1.2.1 Key primary participants 419 17.1.2.2 Breakdown of primary interviews 419 17.1.2.3 Key data from primary sources 420 17.2 MARKET SIZE ESTIMATION 420 17.2.1 GLOBAL VACCINES MARKET SIZE ESTIMATION, 2025 420 17.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up approach) 421 17.2.1.2 Approach 2: Primary research 422 17.2.1.2.1 Key industry insights 423 17.2.1.3 Approach 3: Secondary analysis 423 17.2.1.4 Approach 4: Bottom-up approach (disease indication-based analysis) 423 17.2.1.5 Approach 5: MarketsandMarkets repository analysis 424 17.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH), 2025 424 17.3 MARKET GROWTH RATE PROJECTIONS 426 17.4 DATA TRIANGULATION 428 17.5 RESEARCH ASSUMPTIONS 429 17.6 RESEARCH LIMITATIONS & RISK ASSESSMENT 431 18 APPENDIX 432 18.1 DISCUSSION GUIDE 432 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 436 18.3 CUSTOMIZATION OPTIONS 438 18.4 RELATED REPORTS 438 18.5 AUTHOR DETAILS 439

圖表清單 List of Tables & Figures

TABLE 1 VACCINES MARKET: INCLUSIONS & EXCLUSIONS 41 TABLE 2 VACCINES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 56 TABLE 3 NIH FUNDING FOR VACCINE RESEARCH, 2020–2025 (USD MILLION) 62 TABLE 4 MAJOR COST DRIVERS AND IMPACT ON COST OF GOODS SOLD (COGS) 62 TABLE 5 NOTABLE CANCER VACCINES IN CLINICAL TRIALS 66 TABLE 6 VACCINES MARKET: IMPACT OF PORTER’S FIVE FORCES 72 TABLE 7 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR RSV 78 TABLE 8 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR CANCER 80 TABLE 9 VACCINE PIPELINE PRODUCTS UNDER PHASE 3 CLINICAL TRIALS FOR INFLUENZA 80 TABLE 10 KEY PIPELINE VACCINES: GSK PLC 81 TABLE 11 KEY PIPELINE VACCINES: MERCK & CO., INC. 82 TABLE 12 KEY PIPELINE VACCINES: PFIZER INC. 82 TABLE 13 KEY PIPELINE VACCINES: SANOFI 83 TABLE 14 VACCINES MARKET: ROLE IN ECOSYSTEM 84 TABLE 15 AVERAGE SELLING PRICE TREND OF PEDIATRIC VACCINES, BY KEY PLAYER, 2024–2026 (USD) 86 TABLE 16 AVERAGE SELLING PRICE TREND OF ADULT VACCINES, BY KEY PLAYER, 2024–2026 (USD) 87 TABLE 17 AVERAGE SELLING PRICE TREND OF VACCINES, BY REGION, 2022–2024 (USD) 89 TABLE 18 IMPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND) 91 TABLE 19 IMPORT DATA FOR HS CODE 300220, 2021–2025 (TONS) 92 TABLE 20 EXPORT DATA FOR HS CODE 300220, 2021–2025 (USD THOUSAND) 93 TABLE 21 EXPORT DATA FOR HS CODE 300220, 2021–2025 (TONS) 93 TABLE 22 VACCINES MARKET: KEY CONFERENCES AND EVENTS, 2026–2027 94 TABLE 23 US ADJUSTED RECIPROCAL TARIFF RATES 98 TABLE 24 NUMBER OF VACCINES DELIVERED BY UNICEF, 2024–2026 101 TABLE 25 WHO VACCINE PURCHASE DATABASE, BY PROCUREMENT MECHANISM, 2022–2024 102 TABLE 26 WHO VACCINE PURCHASE DATABASE, BY MANUFACTURER, 2022–2024 103 TABLE 27 WHO VACCINE PURCHASE DATABASE, BY INDICATION, 2022–2024 103 TABLE 28 WHO VACCINE PURCHASE DATABASE, BY REGION, 2022–2024 104 TABLE 29 VACCINE PRODUCTION CAPACITY, BY KEY PLAYER, 2025 105 TABLE 30 KEY VACCINE MANUFACTURING CAPACITY EXPANSIONS, 2025–2026 106 TABLE 31 VACCINES MARKET: INDICATIVE LIST OF PATENTS, 2026 112 TABLE 32 CASE STUDIES OF AI IMPLEMENTATION IN VACCINES MARKET 117 TABLE 33 CLIENT’S READINESS TO ADOPT GENERATIVE AI IN VACCINES 118 TABLE 34 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 119 TABLE 35 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 120 TABLE 36 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121 TABLE 37 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 121 TABLE 38 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY VACCINES 128 TABLE 39 KEY BUYING CRITERIA, BY END USER 129 TABLE 40 VACCINES MARKET, BY DISEASE INDICATION, 2024–2031 (USD MILLION) 133 TABLE 41 LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL DISEASE VACCINES 135 TABLE 42 PNEUMOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 43 NORTH AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 44 EUROPE: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 45 ASIA PACIFIC: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 46 LATIN AMERICA: PNEUMOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 47 LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES 139 TABLE 48 INFLUENZA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 49 NORTH AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 50 EUROPE: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 51 ASIA PACIFIC: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 52 LATIN AMERICA: INFLUENZA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 53 LIST OF COMMERCIALLY AVAILABLE HPV VACCINES 143 TABLE 54 HPV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 144 TABLE 55 NORTH AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 56 EUROPE: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 57 ASIA PACIFIC: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145 TABLE 58 LATIN AMERICA: HPV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 59 LIST OF COMMERCIALLY AVAILABLE HERPES ZOSTER VACCINES 147 TABLE 60 HERPES ZOSTER VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 148 TABLE 61 NORTH AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 62 EUROPE: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 63 ASIA PACIFIC: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 64 LATIN AMERICA: HERPES ZOSTER VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 65 LIST OF COMMERCIALLY AVAILABLE COMBINATION VACCINES 151 TABLE 66 COMBINATION VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 67 NORTH AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 68 EUROPE: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 69 ASIA PACIFIC: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 70 LATIN AMERICA: COMBINATION VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 71 LIST OF COMMERCIALLY AVAILABLE MENINGOCOCCAL DISEASE VACCINES 155 TABLE 72 MENINGOCOCCAL DISEASE VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 73 NORTH AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 74 EUROPE: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 75 ASIA PACIFIC: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 76 LATIN AMERICA: MENINGOCOCCAL DISEASE VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 77 LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES 158 TABLE 78 ROTAVIRUS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 79 NORTH AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 80 EUROPE: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 81 ASIA PACIFIC: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 82 LATIN AMERICA: ROTAVIRUS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 83 LIST OF COMMERCIALLY AVAILABLE RSV VACCINES 162 TABLE 84 RSV VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 85 NORTH AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 86 EUROPE: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 87 ASIA PACIFIC: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 88 LATIN AMERICA: RSV VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 89 LIST OF COMMERCIALLY AVAILABLE DTP VACCINES 165 TABLE 90 DTP VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 166 TABLE 91 NORTH AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 92 EUROPE: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 93 ASIA PACIFIC: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 94 LATIN AMERICA: DTP VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 95 LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES 169 TABLE 96 HEPATITIS VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 97 NORTH AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 98 EUROPE: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 99 ASIA PACIFIC: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 100 LATIN AMERICA: HEPATITIS VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 101 LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES 172 TABLE 102 VARICELLA VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 103 NORTH AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 104 EUROPE: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 105 ASIA PACIFIC: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 106 LATIN AMERICA: VARICELLA VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 107 TOP 10 COUNTRIES WITH MEASLES OUTBREAKS, JANUARY 2025–JULY 2025 175 TABLE 108 LIST OF COMMERCIALLY AVAILABLE MMR VACCINES 176 TABLE 109 MMR VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 110 NORTH AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 111 EUROPE: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 112 ASIA PACIFIC: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 113 LATIN AMERICA: MMR VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 114 POLIO VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 115 NORTH AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 116 EUROPE: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 117 ASIA PACIFIC: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 118 LATIN AMERICA: POLIO VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 119 COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 120 NORTH AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 121 EUROPE: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 122 ASIA PACIFIC: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 123 LATIN AMERICA: COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 124 LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS 185 TABLE 125 VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 126 NORTH AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 127 EUROPE: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 128 ASIA PACIFIC: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 129 LATIN AMERICA: VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 130 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 189 TABLE 131 EXAMPLES OF RECOMBINANT VACCINES 190 TABLE 132 RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 191 TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 137 EXAMPLES OF CONJUGATE VACCINES 194 TABLE 138 CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 194 TABLE 139 NORTH AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 140 EUROPE: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 141 ASIA PACIFIC: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 142 LATIN AMERICA: CONJUGATE VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 143 EXAMPLES OF INACTIVATED & SUBUNIT VACCINES 197 TABLE 144 INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 198 TABLE 145 NORTH AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 146 EUROPE: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 147 ASIA PACIFIC: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 148 LATIN AMERICA: INACTIVATED & SUBUNIT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 149 EXAMPLES OF LIVE ATTENUATED VACCINES 201 TABLE 150 LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 201 TABLE 151 NORTH AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 152 EUROPE: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 153 ASIA PACIFIC: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 154 LATIN AMERICA: LIVE ATTENUATED VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 155 EXAMPLES OF TOXOID VACCINES 204 TABLE 156 TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 204 TABLE 157 NORTH AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 158 EUROPE: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 159 ASIA PACIFIC: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 160 LATIN AMERICA: TOXOID VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 161 OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 207 TABLE 162 NORTH AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 163 EUROPE: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 164 ASIA PACIFIC: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 165 LATIN AMERICA: OTHER VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 166 COVID-19 VACCINES MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 210 TABLE 167 MRNA COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 211 TABLE 168 NORTH AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 169 EUROPE: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 170 ASIA PACIFIC: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 171 LATIN AMERICA: MRNA COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 172 VIRAL VECTOR COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 214 TABLE 173 NORTH AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 174 EUROPE: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 175 ASIA PACIFIC: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 176 LATIN AMERICA: VIRAL VECTOR COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 177 OTHER COVID-19 VACCINES MARKET, BY REGION, 2024–2031 (USD MILLION) 216 TABLE 178 NORTH AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 179 EUROPE: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 180 ASIA PACIFIC: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 181 LATIN AMERICA: OTHER COVID-19 VACCINES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 218 TABLE 182 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 220 TABLE 183 EXAMPLES OF MULTIVALENT VACCINES 221 TABLE 184 MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 222 TABLE 185 NORTH AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 186 EUROPE: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 187 ASIA PACIFIC: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 188 LATIN AMERICA: MULTIVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 189 EXAMPLES OF MONOVALENT VACCINES 225 TABLE 190 MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 226 TABLE 191 NORTH AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 192 EUROPE: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 193 ASIA PACIFIC: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 194 LATIN AMERICA: MONOVALENT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 195 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 230 TABLE 196 ADVANTAGES AND DISADVANTAGES OF INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION 231 TABLE 197 VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 232 TABLE 198 NORTH AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 199 EUROPE: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 200 ASIA PACIFIC: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 201 LATIN AMERICA: VACCINES MARKET FOR INTRAMUSCULAR & SUBCUTANEOUS ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 202 VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 235 TABLE 203 NORTH AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 204 EUROPE: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 205 ASIA PACIFIC: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 236 TABLE 206 LATIN AMERICA: VACCINES MARKET FOR ORAL ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 237 TABLE 207 VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 238 TABLE 208 NORTH AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 238 TABLE 209 EUROPE: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 210 ASIA PACIFIC: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 211 LATIN AMERICA: VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 240 TABLE 212 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 242 TABLE 213 ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 243 TABLE 214 NORTH AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 215 EUROPE: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 244 TABLE 216 ASIA PACIFIC: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 217 LATIN AMERICA: ADULT VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 245 TABLE 218 PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 246 TABLE 219 NORTH AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 220 EUROPE: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 247 TABLE 221 ASIA PACIFIC: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 222 LATIN AMERICA: PEDIATRIC VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 248 TABLE 223 VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY REGION, 2024–2031 (USD MILLION) 250 TABLE 224 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 252 TABLE 225 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 252 TABLE 226 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 227 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 253 TABLE 228 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254 TABLE 229 NORTH AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 254 TABLE 230 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 255 TABLE 231 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 232 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 256 TABLE 233 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 257 TABLE 234 US: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 257 TABLE 235 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 258 TABLE 236 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 237 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 259 TABLE 238 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 259 TABLE 239 CANADA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 260 TABLE 240 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 261 TABLE 241 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 261 TABLE 242 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 243 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 262 TABLE 244 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 263 TABLE 245 EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 263 TABLE 246 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 264 TABLE 247 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 248 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 265 TABLE 249 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266 TABLE 250 GERMANY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 266 TABLE 251 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 267 TABLE 252 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 253 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 268 TABLE 254 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 268 TABLE 255 UK: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 269 TABLE 256 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 270 TABLE 257 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 258 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 271 TABLE 259 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 271 TABLE 260 FRANCE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 272 TABLE 261 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 273 TABLE 262 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 263 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 274 TABLE 264 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 274 TABLE 265 ITALY: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 275 TABLE 266 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 275 TABLE 267 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 268 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 276 TABLE 269 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 277 TABLE 270 SPAIN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 277 TABLE 271 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 278 TABLE 272 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 273 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 279 TABLE 274 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 279 TABLE 275 REST OF EUROPE: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 280 TABLE 276 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 277 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 282 TABLE 278 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 279 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 283 TABLE 280 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 283 TABLE 281 ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 284 TABLE 282 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 285 TABLE 283 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 285 TABLE 284 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 286 TABLE 285 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 286 TABLE 286 CHINA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 287 TABLE 287 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 288 TABLE 288 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 289 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 289 TABLE 290 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 289 TABLE 291 JAPAN: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 290 TABLE 292 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 291 TABLE 293 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 291 TABLE 294 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 292 TABLE 295 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 292 TABLE 296 INDIA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 293 TABLE 297 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 294 TABLE 298 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 299 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 295 TABLE 300 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 295 TABLE 301 SOUTH KOREA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 296 TABLE 302 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 297 TABLE 303 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 304 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 298 TABLE 305 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 298 TABLE 306 REST OF ASIA PACIFIC: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 299 TABLE 307 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY COUNTRY, 2024–2031 (USD MILLION) 299 TABLE 308 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 300 TABLE 309 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 310 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 301 TABLE 311 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 301 TABLE 312 LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 302 TABLE 313 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 303 TABLE 314 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 315 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 304 TABLE 316 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 304 TABLE 317 BRAZIL: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 305 TABLE 318 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 306 TABLE 319 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 320 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 307 TABLE 321 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 307 TABLE 322 MEXICO: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 308 TABLE 323 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 308 TABLE 324 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 325 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 309 TABLE 326 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 310 TABLE 327 REST OF LATIN AMERICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 310 TABLE 328 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 311 TABLE 329 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 311 TABLE 330 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 312 TABLE 331 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 312 TABLE 332 MIDDLE EAST: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 313 TABLE 333 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TECHNOLOGY, 2024–2031 (USD MILLION) 314 TABLE 334 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 335 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY DISEASE INDICATION, 2024–2031 (USD MILLION) 315 TABLE 336 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 315 TABLE 337 AFRICA: VACCINES MARKET (EXCLUDING COVID-19 VACCINES), BY END USER, 2024–2031 (USD MILLION) 316 TABLE 338 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, JANUARY 2023−JULY 2025 317 TABLE 339 VACCINES MARKET: DEGREE OF COMPETITION 321 TABLE 340 VACCINES MARKET: REGION FOOTPRINT 325 TABLE 341 VACCINES MARKET: TECHNOLOGY FOOTPRINT 326 TABLE 342 VACCINES MARKET: TYPE FOOTPRINT 327 TABLE 343 VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 328 TABLE 344 VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 330 TABLE 345 VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 331 TABLE 346 VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 334 TABLE 347 VACCINES MARKET: DEALS, JANUARY 2023–JULY 2026 335 TABLE 348 VACCINES MARKET: EXPANSIONS, JANUARY 2023–JULY 2026 336 TABLE 349 PFIZER INC.: COMPANY OVERVIEW 337 TABLE 350 PFIZER INC.: PRODUCTS OFFERED 338 TABLE 351 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 340 TABLE 352 GSK PLC: COMPANY OVERVIEW 342 TABLE 353 GSK PLC: PRODUCTS OFFERED 343 TABLE 354 GSK PLC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 345 TABLE 355 GSK PLC: DEALS, JANUARY 2023–JULY 2026 347 TABLE 356 GSK PLC: EXPANSIONS, JANUARY 2023–JULY 2026 347 TABLE 357 MERCK & CO., INC.: COMPANY OVERVIEW 349 TABLE 358 MERCK & CO., INC.: PRODUCTS OFFERED 350 TABLE 359 MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 352 TABLE 360 MERCK & CO., INC.: EXPANSIONS, JANUARY 2023–JULY 2026 353 TABLE 361 SANOFI: COMPANY OVERVIEW 354 TABLE 362 SANOFI: PRODUCTS OFFERED 355 TABLE 363 SANOFI: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 357 TABLE 364 SANOFI: DEALS, JANUARY 2023–JULY 2026 357 TABLE 365 SANOFI: EXPANSIONS, JANUARY 2023–JULY 2026 358 TABLE 366 SANOFI: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 359 TABLE 367 CSL: COMPANY OVERVIEW 360 TABLE 368 CSL: PRODUCTS OFFERED 361 TABLE 369 CSL: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 362 TABLE 370 CSL: DEALS, JANUARY 2023–JULY 2026 362 TABLE 371 CSL: EXPANSIONS, JANUARY 2023–JULY 2026 363 TABLE 372 EMERGENT: COMPANY OVERVIEW 364 TABLE 373 EMERGENT: PRODUCTS OFFERED 365 TABLE 374 EMERGENT: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 366 TABLE 375 EMERGENT: DEALS, JANUARY 2023–JULY 2026 367 TABLE 376 EMERGENT: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 367 TABLE 377 JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW 368 TABLE 378 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED 369 TABLE 379 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2023–JULY 2026 370 TABLE 380 ASTRAZENECA: COMPANY OVERVIEW 371 TABLE 381 ASTRAZENECA: PRODUCTS OFFERED 372 TABLE 382 ASTRAZENECA: DEALS, JANUARY 2023–JULY 2026 373 TABLE 383 ASTRAZENECA: EXPANSIONS, JANUARY 2023–JULY 2026 373 TABLE 384 SERUM INSTITUTE OF INDIA PVT. LTD.: COMPANY OVERVIEW 374 TABLE 385 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS OFFERED (SUPPLIED OVERSEAS) 374 TABLE 386 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS OFFERED (SUPPLIED IN INDIA) 376 TABLE 387 SERUM INSTITUTE OF INDIA PVT. LTD.: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 377 TABLE 388 SERUM INSTITUTE OF INDIA PVT. LTD.: DEALS, JANUARY 2023–JULY 2026 378 TABLE 389 SERUM INSTITUTE OF INDIA PVT. LTD.: EXPANSIONS, JANUARY 2023–JULY 2026 380 TABLE 390 BAVARIAN NORDIC: COMPANY OVERVIEW 381 TABLE 391 BAVARIAN NORDIC: PRODUCTS OFFERED 382 TABLE 392 BAVARIAN NORDIC: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 383 TABLE 393 BAVARIAN NORDIC: DEALS, JANUARY 2023–JULY 2026 384 TABLE 394 BAVARIAN NORDIC: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 385 TABLE 395 TANABE PHARMA CORPORATION: COMPANY OVERVIEW 386 TABLE 396 TANABE PHARMA CORPORATION: PRODUCTS OFFERED 386 TABLE 397 TANABE PHARMA CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 387 TABLE 398 TANABE PHARMA CORPORATION: DEALS, JANUARY 2023–JULY 2026 387 TABLE 399 DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW 388 TABLE 400 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED 389 TABLE 401 DAIICHI SANKYO COMPANY, LIMITED: DEALS, JANUARY 2023–JULY 2026 390 TABLE 402 PANACEA BIOTEC: COMPANY OVERVIEW 391 TABLE 403 PANACEA BIOTEC: PRODUCTS OFFERED 392 TABLE 404 PANACEA BIOTEC: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 393 TABLE 405 BIOLOGICAL E. LIMITED: COMPANY OVERVIEW 394 TABLE 406 BIOLOGICAL E. LIMITED: PRODUCTS OFFERED (INDIAN MARKET) 394 TABLE 407 BIOLOGICAL E. LIMITED: PRODUCTS OFFERED (INTERNATIONAL MARKET) 395 TABLE 408 BIOLOGICAL E. LIMITED: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 396 TABLE 409 BIOLOGICAL E. LIMITED: DEALS, JANUARY 2023–JULY 2026 397 TABLE 410 BIOLOGICAL E. LIMITED: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 397 TABLE 411 BHARAT BIOTECH: COMPANY OVERVIEW 398 TABLE 412 BHARAT BIOTECH: PRODUCTS OFFERED 398 TABLE 413 BHARAT BIOTECH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JULY 2026 399 TABLE 414 BHARAT BIOTECH: DEALS, JANUARY 2023–JULY 2026 400 TABLE 415 NOVAVAX: COMPANY OVERVIEW 401 TABLE 416 NOVAVAX: PRODUCTS OFFERED 402 TABLE 417 NOVAVAX: PRODUCT APPROVALS, JANUARY 2023–JULY 2026 402 TABLE 418 NOVAVAX: DEALS, JANUARY 2023–JULY 2026 403 TABLE 419 INOVIO PHARMACEUTICALS: COMPANY OVERVIEW 404 TABLE 420 INOVIO PHARMACEUTICALS: PRODUCTS OFFERED 405 TABLE 421 INOVIO PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2023–JULY 2026 405 TABLE 422 SINOVAC: COMPANY OVERVIEW 406 TABLE 423 INCEPTA PHARMACEUTICALS LTD.: COMPANY OVERVIEW 408 TABLE 424 VALNEVA SE: COMPANY OVERVIEW 410 TABLE 425 EUBIOLOGICS CO., LTD.: COMPANY OVERVIEW 411 TABLE 426 BIO FARMA: COMPANY OVERVIEW 412 TABLE 427 MICROGEN: COMPANY OVERVIEW 414 TABLE 428 CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD: COMPANY OVERVIEW 415 TABLE 429 INDIAN IMMUNOLOGICALS LIMITED: COMPANY OVERVIEW 416 TABLE 430 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 427 TABLE 431 VACCINES MARKET: RISK ASSESSMENT 431 FIGURE 1 VACCINES MARKET SEGMENTATION & REGIONS COVERED 40 FIGURE 2 MARKET SCENARIO 44 FIGURE 3 GLOBAL VACCINES MARKET (INCLUDING COVID-19 VACCINES), 2024–2031 45 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN VACCINES MARKET, 2023–2026 46 FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VACCINES MARKET 47 FIGURE 6 HIGH-GROWTH SEGMENTS IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), 2026–2031 48 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN VACCINES MARKET (EXCLUDING COVID-19 VACCINES), IN TERMS OF VALUE, DURING FORECAST PERIOD 49 FIGURE 8 FOCUS ON VACCINE DEVELOPMENT AND LAUNCHES TO DRIVE MARKET GROWTH 51 FIGURE 9 US AND MULTIVALENT VACCINES ACCOUNTED FOR THE LARGEST SHARE OF THE VACCINES MARKET IN NORTH AMERICA IN 2025 52 FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET DURING 2026–2031 53 FIGURE 11 INTRAMUSCULAR AND SUBCUTANEOUS ROUTE TO DOMINATE MARKET DURING FORECAST PERIOD 54 FIGURE 12 VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 FIGURE 13 US: NOVEL INFLUENZA A VIRUS CASES, BY SEASON (2010–2011 TO 2025–2026 SEASON) 58 FIGURE 14 MANUFACTURING-RELATED PARAMETERS INCLUDED IN COST MODEL 64 FIGURE 15 US: ESTIMATED NUMBER OF NEW CANCER CASES AND DEATHS BY SITE, 2025 65 FIGURE 16 VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 72 FIGURE 17 GLOBAL GDP GROWTH, 2020–2030 75 FIGURE 18 VACCINES MARKET: VALUE CHAIN ANALYSIS 76 FIGURE 19 VACCINES MARKET: CLINICAL TRIALS, BY PHASE 77 FIGURE 20 VACCINES MARKET: CLINICAL TRIALS, BY DISEASE INDICATION 78 FIGURE 21 VACCINES MARKET ECOSYSTEM 84 FIGURE 22 AVERAGE SELLING PRICE TREND OF VACCINES, BY DISEASE INDICATION, 2024–2026 (USD) 88 FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN VACCINES MARKET 96 FIGURE 24 VACCINES MARKET: PHARMACEUTICAL M&A DEAL ACTIVITY, NUMBER, AND AGGREGATE TOTAL VALUE, 2021–2025 97 FIGURE 25 TOP APPLICANTS/OWNERS (COMPANIES) FOR VACCINE PATENTS, 2015–2025 112 FIGURE 26 IMPACT OF AI/GEN AI ON VACCINES MARKET 116 FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VACCINES 127 FIGURE 28 KEY BUYING CRITERIA, BY END USER 129 FIGURE 29 NORTH AMERICA: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 251 FIGURE 30 ASIA PACIFIC: VACCINES MARKET SNAPSHOT (EXCLUDING COVID-19 VACCINES) 281 FIGURE 31 REVENUE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2021–2025 (USD BILLION) 320 FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS IN VACCINES MARKET, 2025 321 FIGURE 33 VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 324 FIGURE 34 VACCINES MARKET: COMPANY FOOTPRINT 325 FIGURE 35 VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 329 FIGURE 36 EV/EBITDA OF KEY VENDORS 332 FIGURE 37 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 332 FIGURE 38 VACCINES MARKET: PRODUCT COMPARATIVE ANALYSIS 333 FIGURE 39 PFIZER INC.: COMPANY SNAPSHOT (2025) 338 FIGURE 40 GSK PLC: COMPANY SNAPSHOT (2025) 343 FIGURE 41 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 350 FIGURE 42 SANOFI: COMPANY SNAPSHOT (2025) 355 FIGURE 43 CSL: COMPANY SNAPSHOT (2025) 361 FIGURE 44 EMERGENT: COMPANY SNAPSHOT (2025) 365 FIGURE 45 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2025) 369 FIGURE 46 ASTRAZENECA: COMPANY SNAPSHOT (2025) 372 FIGURE 47 BAVARIAN NORDIC: COMPANY SNAPSHOT (2025) 382 FIGURE 48 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2025) 389 FIGURE 49 PANACEA BIOTEC: COMPANY SNAPSHOT (2024) 392 FIGURE 50 NOVAVAX: COMPANY SNAPSHOT (2025) 401 FIGURE 51 INOVIO PHARMACEUTICALS: COMPANY SNAPSHOT (2025) 404 FIGURE 52 VACCINES MARKET: RESEARCH DESIGN 417 FIGURE 53 VACCINES MARKET: BREAKDOWN OF PRIMARIES 419 FIGURE 54 GLOBAL VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 420 FIGURE 55 GLOBAL VACCINES MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 421 FIGURE 56 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE ANALYSIS, 2025 422 FIGURE 57 VACCINES MARKET: INSIGHTS FROM PRIMARIES 423 FIGURE 58 ILLUSTRATIVE EXAMPLE OF INFLUENZA VACCINES: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025 424 FIGURE 59 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 425 FIGURE 60 VACCINES MARKET: CAGR PROJECTIONS 427 FIGURE 61 VACCINES MARKET: DATA TRIANGULATION 429

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們